The stock of Zomedica Corp (ZOM) has seen a -1.85% decrease in the past week, with a -5.55% drop in the past month, and a -9.70% decrease in the past quarter. The volatility ratio for the week is 3.76%, and the volatility levels for the past 30 days are at 3.59% for ZOM. The simple moving average for the last 20 days is -1.12% for ZOM stock, with a simple moving average of -13.70% for the last 200 days.
Is It Worth Investing in Zomedica Corp (AMEX: ZOM) Right Now?
The stock has a 36-month beta value of 1.03. Opinions on the stock are mixed, with 0 analysts rating it as a “buy,” 0 as “overweight,” 1 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for ZOM is 962.51M, and at present, short sellers hold a 5.11% of that float. On September 24, 2024, the average trading volume of ZOM was 3.18M shares.
ZOM) stock’s latest price update
The stock price of Zomedica Corp (AMEX: ZOM) has plunged by -6.31 when compared to previous closing price of 0.14, but the company has seen a -1.85% decline in its stock price over the last five trading sessions. accesswire.com reported 2024-09-11 that Expanded cleanroom and improved distribution facilities enhance manufacturing capacity and shipping efficiencies ANN ARBOR, MI / ACCESSWIRE / September 11, 2024 / Zomedica Corp. (NYSE American:ZOM) (“Zomedica” or the “Company”), a veterinary health company offering diagnostic and therapeutic products for equine and companion animals, is pleased to announce the completion of renovations at its 30,000-square-foot manufacturing, distribution, and research and development (R&D) facility in Plymouth, Minnesota. Highlights of the renovation include: Expanded cleanroom for manufacturing operations Installation and validation of new automated line to produce TRUFORMA® consumable cartridges Improved distribution facilities for more efficient and streamlined shipping of TRUFORMA cartridges “With the steady growth of our TRUFORMA product line, these facility renovations, and new automated production equipment have increased manufacturing capacity which we believe will meet increasing demand for TRUFORMA cartridges for years to come,” stated Larry Heaton, Zomedica’s Chief Executive Officer.
Analysts’ Opinion of ZOM
Many brokerage firms have already submitted their reports for ZOM stocks, with Dawson James repeating the rating for ZOM by listing it as a “Buy.” The predicted price for ZOM in the upcoming period, according to Dawson James is $6 based on the research report published on January 06, 2023 of the previous year 2023.
ZOM Trading at -9.30% from the 50-Day Moving Average
After a stumble in the market that brought ZOM to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -44.16% of loss for the given period.
Volatility was left at 3.59%, however, over the last 30 days, the volatility rate increased by 3.76%, as shares sank -6.52% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -16.11% lower at present.
During the last 5 trading sessions, ZOM fell by -1.85%, which changed the moving average for the period of 200-days by -24.63% in comparison to the 20-day moving average, which settled at $0.1286. In addition, Zomedica Corp saw -36.26% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ZOM starting from HEATON LARRY C II, who purchase 100,000 shares at the price of $0.12 back on Sep 05 ’24. After this action, HEATON LARRY C II now owns 400,000 shares of Zomedica Corp, valued at $12,500 using the latest closing price.
POWERS JOHNNY D, the Director of Zomedica Corp, purchase 100,000 shares at $0.13 during a trade that took place back on Aug 28 ’24, which means that POWERS JOHNNY D is holding 2,325,000 shares at $12,900 based on the most recent closing price.
Stock Fundamentals for ZOM
Current profitability levels for the company are sitting at:
- -1.41 for the present operating margin
- 0.54 for the gross margin
The net margin for Zomedica Corp stands at -2.15. The total capital return value is set at -0.17. Equity return is now at value -23.92, with -22.64 for asset returns.
Based on Zomedica Corp (ZOM), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -9.62. The debt to equity ratio resting at 0.01. The interest coverage ratio of the stock is 128.1.
Currently, EBITDA for the company is -25.29 million with net debt to EBITDA at 0.18. When we switch over and look at the enterprise to sales, we see a ratio of 4.58. The receivables turnover for the company is 12.38for trailing twelve months and the total asset turnover is 0.12. The liquidity ratio also appears to be rather interesting for investors as it stands at 11.39.
Conclusion
To sum up, Zomedica Corp (ZOM) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
